TITLE:
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.

CONDITION:
Colorectal Cancer

INTERVENTION:
ALIMTA

SUMMARY:

      This is a non-randomized study in patients who have received prior 5-FU therapy for
      colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of
      ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of
      this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA
      and irinotecan will be given every 21 days.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of locally or metastatic colorectal cancer

          -  Prior therapy with 5-FU for metastatic cancer

          -  Adequate bone marrow, liver and kidney function

        Exclusion Criteria:

          -  Pregnancy

          -  Breast feeding

          -  Inability to interrupt aspirin therapy

          -  Brain metastasis

          -  Patients who have been treated previously with ALIMTA or irinotecan
      
